| 摘要 |
A method of treatment comprising administering an anti-PD-L1 (programmed death ligand 1, B7-H1 or CD274) antibody and an anti-CTLA4 (cytotoxic T lymphocyte antigen-4 or CD152) antibody, or antigen binding fragments thereof, to a patient identified as having a lung cancer that is negative for PD-L1. Preferably the anti-PD-L1 antibody if MEDI4736 (durvalumab) and the CTLA4 antibody is tremelimumab. The lung cancer is preferably a non-small cell lung cancer (NSCLC) selected from the group consisting of squamous cell carcinoma, adenocarcinoma, large cell carcinoma, adenosquamous carcinoma and sarcomatoid carcinoma. Preferably the method comprises administering between about 1mg/kg and 20mg/kg MEDI4736 and between about 1mg/kg and 10mg/kg tremelimumab or antigen binding fragments thereof to a patient identified as having lung cancer negative for PD-L1. |
